Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years.

Jullien V, Urien S, Hirt D, Delaugerre C, Rey E, Teglas JP, Vaz P, Rouzioux C, Chaix ML, Macassa E, Firtion G, Pons G, Blanche S, Tréluyer JM.

Antimicrob Agents Chemother. 2006 Nov;50(11):3548-55. Epub 2006 Aug 28.

2.

Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis.

Jullien V, Raïs A, Urien S, Dimet J, Delaugerre C, Bouillon-Pichault M, Rey E, Pons G, Blanche S, Tréluyer JM.

Br J Clin Pharmacol. 2007 Jul;64(1):105-9. Epub 2007 Feb 26.

3.

Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment.

Bouillon-Pichault M, Jullien V, Azria E, Pannier E, Firtion G, Krivine A, Compagnucci A, Taulera O, Finkielsztejn L, Chhun S, Pons G, Launay O, Treluyer JM.

J Antimicrob Chemother. 2009 Jun;63(6):1223-32. doi: 10.1093/jac/dkp123. Epub 2009 Apr 22.

PMID:
19389715
4.

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

Urien S, Firtion G, Anderson ST, Hirt D, Solas C, Peytavin G, Faye A, Thuret I, Leprevost M, Giraud C, Lyall H, Khoo S, Blanche S, Tréluyer JM.

Br J Clin Pharmacol. 2011 Jun;71(6):956-60. doi: 10.1111/j.1365-2125.2011.03926.x.

5.

A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients.

Bouillon-Pichault M, Jullien V, Piketty C, Viard JP, Morini JP, Chhun S, Krivine A, Salmon D, Dupin N, Weiss L, Lortholary O, Pons G, Launay O, Treluyer JM.

Antivir Ther. 2009;14(7):923-9. doi: 10.3851/IMP1414.

PMID:
19918096
6.

Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years.

Pitsiu M, Hussein Z, Majid O, Aarons L, de Longueville M, Stockis A.

Br J Clin Pharmacol. 2004 Apr;57(4):402-11.

7.

Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis.

Anderson BJ, Pons G, Autret-Leca E, Allegaert K, Boccard E.

Paediatr Anaesth. 2005 Apr;15(4):282-92.

PMID:
15787918
8.

Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.

Jullien V, Tréluyer JM, Rey E, Jaffray P, Krivine A, Moachon L, Lillo-Le Louet A, Lescoat A, Dupin N, Salmon D, Pons G, Urien S.

Antimicrob Agents Chemother. 2005 Aug;49(8):3361-6. Erratum in: Antimicrob Agents Chemother. 2008 Feb;52(2):808.

9.

Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.

Moltó J, Valle M, Miranda C, Cedeño S, Miranda J, Santos JR, Negredo E, Vilaró J, Costa J, Clotet B.

J Antimicrob Chemother. 2008 Oct;62(4):784-92. doi: 10.1093/jac/dkn268. Epub 2008 Jun 30.

PMID:
18593723
10.

Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.

Perucca E, Cloyd J, Critchley D, Fuseau E.

Epilepsia. 2008 Jul;49(7):1123-41. doi: 10.1111/j.1528-1167.2008.01665.x.

11.

Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models.

Driscoll MS, Ludden TM, Casto DT, Littlefield LC.

J Pharmacokinet Biopharm. 1989 Apr;17(2):141-68.

PMID:
2795453
12.

Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients.

Lee JY, Hahn HJ, Son IJ, Suh KS, Yi NJ, Oh JM, Shin WG.

Pharmacotherapy. 2006 Aug;26(8):1069-77.

PMID:
16863483
13.

A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults.

van der Leur MR, Burger DM, la Porte CJ, Koopmans PP.

Ther Drug Monit. 2006 Oct;28(5):650-3.

PMID:
17038880
14.

Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.

Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Urien S.

Antimicrob Agents Chemother. 2006 Jun;50(6):2079-86.

15.

Clonidine disposition in children; a population analysis.

Potts AL, Larsson P, Eksborg S, Warman G, Lönnqvist PA, Anderson BJ.

Paediatr Anaesth. 2007 Oct;17(10):924-33.

PMID:
17767627
16.

Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.

Verweel G, Burger DM, Sheehan NL, Bergshoeff AS, Warris A, van der Knaap LC, Driessen G, de Groot R, Hartwig NG.

Antivir Ther. 2007;12(4):453-8.

PMID:
17668553
17.

Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection.

Mirochnick M, Cooper E, Capparelli E, McIntosh K, Lindsey J, Xu J, Jacobus D, Mofenson L, Bonagura VR, Nachman S, Yogev R, Sullivan JL, Spector SA.

Clin Pharmacol Ther. 2001 Jul;70(1):24-32.

PMID:
11452241
18.

Determination of population pharmacokinetic parameters for amikacin in neonates using mixed-effect models.

Botha JH, du Preez MJ, Miller R, Adhikari M.

Eur J Clin Pharmacol. 1998 Jan;53(5):337-41.

PMID:
9516033
19.

Population pharmacokinetics of amlodipine in hypertensive children and adolescents.

Flynn JT, Nahata MC, Mahan JD Jr, Portman RJ; PATH-2 Investigators.

J Clin Pharmacol. 2006 Aug;46(8):905-16.

PMID:
16855075
20.

Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.

Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G.

Epilepsia. 2009 May;50(5):1150-7. doi: 10.1111/j.1528-1167.2008.01974.x. Epub 2009 Jan 19.

Supplemental Content

Support Center